KEGG   PATHWAY: epz05235
Entry
epz05235                    Pathway                                
Name
PD-L1 expression and PD-1 checkpoint pathway in cancer - Equus przewalskii (Przewalski's horse)
Description
Programmed cell death 1 (PD1) and its ligand (PDL1) are key regulatory physiological immune checkpoints that maintain self-tolerance in the organism by regulating the degree of activation of T and B  cells amongst other immune cell types. In solid tumors, the PD-1/PD-L1 inhibitory pathway can be (mis-)used to silence the immune system by increasing the expression of PD-L1 on the tumor cell surface. Up-regulation of PD-L1 is caused by activation of pro-survival pathways MAPK and PI3K/Akt as well as transcriptional factors HIF-1, STAT3 and NF-kappa B. The MAPK and PI3K signalling pathways are activated by gene mutations and growth factors. PD-L1 on tumor cells may then engage the PD-1 receptors resulting in suppression of T-cell mediated immune response. Therapeutic antibodies blocking the PD-1/PD-L1 pathway by targeting PD-L1 or PD-1 are highly effective in rescuing T cell anti-tumor effector functions.
Class
Human Diseases; Cancer: overview
Pathway map
epz05235  PD-L1 expression and PD-1 checkpoint pathway in cancer
epz05235

Organism
Equus przewalskii (Przewalski's horse) [GN:epz]
Gene
103562790  HIF1A; hypoxia inducible factor 1 alpha subunit [KO:K08268]
103543333  pro-epidermal growth factor-like [KO:K04357]
103560128  EGFR; epidermal growth factor receptor [KO:K04361] [EC:2.7.10.1]
103567332  HRAS; HRas proto-oncogene, GTPase [KO:K02833]
103546629  KRAS; KRAS proto-oncogene, GTPase [KO:K07827]
103552675  NRAS; neuroblastoma RAS viral oncogene homolog [KO:K07828]
103554541  RAF1; Raf-1 proto-oncogene, serine/threonine kinase [KO:K04366] [EC:2.7.11.1]
103549630  MAP2K1; mitogen-activated protein kinase kinase 1 [KO:K04368] [EC:2.7.12.2]
103543290  dual specificity mitogen-activated protein kinase kinase 2-like [KO:K04369] [EC:2.7.12.2]
103547261  MAPK3; mitogen-activated protein kinase 3 [KO:K04371] [EC:2.7.11.24]
103562408  MAPK1; mitogen-activated protein kinase 1 [KO:K04371] [EC:2.7.11.24]
103548618  FOS; Fos proto-oncogene, AP-1 transcription factor subunit [KO:K04379]
103557606  EML4; echinoderm microtubule associated protein like 4 [KO:K15420]
103549200  ALK; anaplastic lymphoma receptor tyrosine kinase [KO:K05119] [EC:2.7.10.1]
103548220  PIK3R1; phosphoinositide-3-kinase regulatory subunit 1 [KO:K02649]
103551868  PIK3R3; phosphoinositide-3-kinase regulatory subunit 3 [KO:K02649]
103561550  PIK3R2; phosphoinositide-3-kinase regulatory subunit 2 [KO:K02649]
103549076  PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta [KO:K00922] [EC:2.7.1.153]
103554655  phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform-like [KO:K00922] [EC:2.7.1.153]
103552150  PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha [KO:K00922] [EC:2.7.1.153]
103561454  PTEN; phosphatase and tensin homolog [KO:K01110] [EC:3.1.3.16 3.1.3.48 3.1.3.67]
103560497  AKT2; AKT serine/threonine kinase 2 [KO:K04456] [EC:2.7.11.1]
103540249  AKT1; AKT serine/threonine kinase 1 [KO:K04456] [EC:2.7.11.1]
103555421  AKT3; AKT serine/threonine kinase 3 [KO:K04456] [EC:2.7.11.1]
103552237  MTOR; mechanistic target of rapamycin [KO:K07203] [EC:2.7.11.1]
103565282  RPS6KB1; ribosomal protein S6 kinase B1 [KO:K04688] [EC:2.7.11.1]
103559935  RPS6KB2; ribosomal protein S6 kinase B2 [KO:K04688] [EC:2.7.11.1]
103567228  CHUK; conserved helix-loop-helix ubiquitous kinase [KO:K04467] [EC:2.7.11.10]
103562903  IKBKB; inhibitor of nuclear factor kappa B kinase subunit beta [KO:K07209] [EC:2.7.11.10]
103543979  NF-kappa-B essential modulator-like [KO:K07210]
103546400  NFKBIA; NFKB inhibitor alpha [KO:K04734]
103564558  NFKBIB; NFKB inhibitor beta [KO:K02581]
103564900  NFKBIE; NFKB inhibitor epsilon [KO:K05872]
103556719  NFKB1; nuclear factor kappa B subunit 1 [KO:K02580]
103543692  RELA; RELA proto-oncogene, NF-kB subunit [KO:K04735]
103559339  IFNG; interferon gamma [KO:K04687]
103549045  IFNGR1; interferon gamma receptor 1 [KO:K05132]
103549109  IFNGR2; interferon gamma receptor 2 [KO:K05133]
103560394  JAK1; Janus kinase 1 [KO:K11217] [EC:2.7.10.2]
103554269  JAK2; Janus kinase 2 [KO:K04447] [EC:2.7.10.2]
103548655  STAT1; signal transducer and activator of transcription 1 [KO:K11220]
103550364  STAT3; signal transducer and activator of transcription 3 [KO:K04692]
103553736  TLR2; toll like receptor 2 [KO:K10159]
103562040  TLR4; toll like receptor 4 [KO:K10160]
103546489  TLR9; toll like receptor 9 [KO:K10161]
103549023  TIRAP; TIR domain containing adaptor protein [KO:K05403]
103557961  MYD88; myeloid differentiation primary response 88 [KO:K04729]
103560236  TRAF6; TNF receptor associated factor 6 [KO:K03175] [EC:2.3.2.27]
103563745  nuclear factor of activated T-cells, cytoplasmic 1-like [KO:K04446]
103554877  NFATC2; nuclear factor of activated T-cells 2 [KO:K17332]
103549708  NFATC3; nuclear factor of activated T-cells 3 [KO:K17333]
103545173  TICAM1; toll like receptor adaptor molecule 1 [KO:K05842]
103546969  TICAM2; toll like receptor adaptor molecule 2 [KO:K05409]
103554263  CD274; CD274 molecule [KO:K06745]
103560349  PDCD1; programmed cell death 1 [KO:K06744]
103547027  PTPN6; protein tyrosine phosphatase, non-receptor type 6 [KO:K05697] [EC:3.1.3.48]
103557133  PTPN11; protein tyrosine phosphatase, non-receptor type 11 [KO:K07293] [EC:3.1.3.48]
103558567  tyrosine-protein phosphatase non-receptor type 11-like [KO:K07293] [EC:3.1.3.48]
103554320  BATF3; basic leucine zipper ATF-like transcription factor 3 [KO:K09034]
103548624  BATF; basic leucine zipper ATF-like transcription factor [KO:K09034]
103559136  BATF2; basic leucine zipper ATF-like transcription factor 2 [KO:K09034]
103556912  CSNK2A1; casein kinase 2 alpha 1 [KO:K03097] [EC:2.7.11.1]
103557853  CSNK2A2; casein kinase 2 alpha 2 [KO:K03097] [EC:2.7.11.1]
103562479  CSNK2B; casein kinase 2 beta [KO:K03115]
103547015  CD4; CD4 molecule [KO:K06454]
103552084  LCK; LCK proto-oncogene, Src family tyrosine kinase [KO:K05856] [EC:2.7.10.2]
103546676  CD3E; CD3e molecule [KO:K06451]
103546674  CD3G; CD3g molecule [KO:K06452]
103541108  uncharacterized LOC103541108 [KO:K10784]
103567401  uncharacterized LOC103567401 [KO:K10784]
103564100  uncharacterized LOC103564100 [KO:K10785]
103542083  uncharacterized LOC103542083 [KO:K10785]
103551552  CD247; CD247 molecule [KO:K06453]
103546675  CD3D; CD3d molecule [KO:K06450]
103561441  ZAP70; zeta-chain (TCR) associated protein kinase 70kDa [KO:K07360] [EC:2.7.10.2]
103549765  MAP3K3; mitogen-activated protein kinase kinase kinase 3 [KO:K04421] [EC:2.7.11.25]
103563092  MAP2K3; mitogen-activated protein kinase kinase 3 [KO:K04432] [EC:2.7.12.2]
103564566  MAP2K6; mitogen-activated protein kinase kinase 6 [KO:K04433] [EC:2.7.12.2]
103565534  MAPK14; mitogen-activated protein kinase 14 [KO:K04441] [EC:2.7.11.24]
103563198  MAPK13; mitogen-activated protein kinase 13 [KO:K04441] [EC:2.7.11.24]
103559485  MAPK12; mitogen-activated protein kinase 12 [KO:K04441] [EC:2.7.11.24]
103559491  MAPK11; mitogen-activated protein kinase 11 [KO:K04441] [EC:2.7.11.24]
103562729  LAT; linker for activation of T-cells [KO:K07362]
103562208  PLCG1; phospholipase C gamma 1 [KO:K01116] [EC:3.1.4.11]
103549452  PPP3CB; protein phosphatase 3 catalytic subunit beta [KO:K04348] [EC:3.1.3.16]
103552390  PPP3CA; protein phosphatase 3 catalytic subunit alpha [KO:K04348] [EC:3.1.3.16]
103552773  PPP3CC; protein phosphatase 3 catalytic subunit gamma [KO:K04348] [EC:3.1.3.16]
103548960  PPP3R1; protein phosphatase 3 regulatory subunit B, alpha [KO:K06268]
103552460  PPP3R2; protein phosphatase 3 regulatory subunit B, beta [KO:K06268]
103560184  RASGRP1; RAS guanyl releasing protein 1 [KO:K04350]
103557389  CD28; CD28 molecule [KO:K06470]
103557074  PRKCQ; protein kinase C theta [KO:K18052] [EC:2.7.11.13]
Compound
C00076  Calcium cation
C00165  Diacylglycerol
C01245  D-myo-Inositol 1,4,5-trisphosphate
C05981  Phosphatidylinositol-3,4,5-trisphosphate
Reference
  Authors
Kythreotou A, Siddique A, Mauri FA, Bower M, Pinato DJ
  Title
PD-L1.
  Journal
J Clin Pathol 71:189-194 (2018)
DOI:10.1136/jclinpath-2017-204853
Reference
  Authors
Zhou TC, Sankin AI, Porcelli SA, Perlin DS, Schoenberg MP, Zang X
  Title
A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
  Journal
Urol Oncol 35:14-20 (2017)
DOI:10.1016/j.urolonc.2016.10.004
Reference
  Authors
Wang Y, Wang H, Yao H, Li C, Fang JY, Xu J
  Title
Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion.
  Journal
Front Pharmacol 9:536 (2018)
DOI:10.3389/fphar.2018.00536
Reference
  Authors
Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, Wu X, Ma J, Zhou M, Li X, Li Y, Li G, Xiong W, Guo C, Zeng Z
  Title
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape.
  Journal
Mol Cancer 18:10 (2019)
DOI:10.1186/s12943-018-0928-4
Reference
  Authors
Bardhan K, Anagnostou T, Boussiotis VA
  Title
The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation.
  Journal
Front Immunol 7:550 (2016)
DOI:10.3389/fimmu.2016.00550
Reference
  Authors
Shi Y
  Title
Regulatory mechanisms of PD-L1 expression in cancer cells.
  Journal
Cancer Immunol Immunother 67:1481-1489 (2018)
DOI:10.1007/s00262-018-2226-9
Reference
  Authors
Zerdes I, Matikas A, Bergh J, Rassidakis GZ, Foukakis T
  Title
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations.
  Journal
Oncogene 37:4639-4661 (2018)
DOI:10.1038/s41388-018-0303-3
Reference
  Authors
Chen J, Jiang CC, Jin L, Zhang XD
  Title
Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
  Journal
Ann Oncol 27:409-16 (2016)
DOI:10.1093/annonc/mdv615
Reference
  Authors
Glodde N, Holzel M
  Title
RAS and PD-L1: A Masters' Liaison in Cancer Immune Evasion.
  Journal
Immunity 47:1007-1009 (2017)
DOI:10.1016/j.immuni.2017.12.001
Reference
  Authors
Ritprajak P, Azuma M
  Title
Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma.
  Journal
Oral Oncol 51:221-8 (2015)
DOI:10.1016/j.oraloncology.2014.11.014
Reference
  Authors
Nirschl CJ, Drake CG
  Title
Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy.
  Journal
Clin Cancer Res 19:4917-24 (2013)
DOI:10.1158/1078-0432.CCR-12-1972
Reference
  Authors
Saeidi A, Zandi K, Cheok YY, Saeidi H, Wong WF, Lee CYQ, Cheong HC, Yong YK, Larsson M, Shankar EM
  Title
T-Cell Exhaustion in Chronic Infections: Reversing the State of Exhaustion and Reinvigorating Optimal Protective Immune Responses.
  Journal
Front Immunol 9:2569 (2018)
DOI:10.3389/fimmu.2018.02569
Reference
  Authors
Sharpe AH, Pauken KE
  Title
The diverse functions of the PD1 inhibitory pathway.
  Journal
Nat Rev Immunol 18:153-167 (2018)
DOI:10.1038/nri.2017.108
Reference
  Authors
Boussiotis VA
  Title
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.
  Journal
N Engl J Med 375:1767-1778 (2016)
DOI:10.1056/NEJMra1514296
Reference
  Authors
Arasanz H, Gato-Canas M, Zuazo M, Ibanez-Vea M, Breckpot K, Kochan G, Escors D
  Title
PD1 signal transduction pathways in T cells.
  Journal
Oncotarget 8:51936-51945 (2017)
DOI:10.18632/oncotarget.17232
Reference
  Authors
Zuazo M, Gato-Canas M, Llorente N, Ibanez-Vea M, Arasanz H, Kochan G, Escors D
  Title
Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy.
  Journal
Ann Transl Med 5:385 (2017)
DOI:10.21037/atm.2017.06.11
Reference
  Authors
Patsoukis N, Li L, Sari D, Petkova V, Boussiotis VA
  Title
PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2.
  Journal
Mol Cell Biol 33:3091-8 (2013)
DOI:10.1128/MCB.00319-13
Reference
  Authors
Chinai JM, Janakiram M, Chen F, Chen W, Kaplan M, Zang X
  Title
New immunotherapies targeting the PD-1 pathway.
  Journal
Trends Pharmacol Sci 36:587-95 (2015)
DOI:10.1016/j.tips.2015.06.005
Reference
  Authors
Ok CY, Young KH
  Title
Targeting the programmed death-1 pathway in lymphoid neoplasms.
  Journal
Cancer Treat Rev 54:99-109 (2017)
DOI:10.1016/j.ctrv.2017.01.009
Related
pathway
epz04010  MAPK signaling pathway
epz04020  Calcium signaling pathway
epz04066  HIF-1 signaling pathway
epz04151  PI3K-Akt signaling pathway
epz04514  Cell adhesion molecules
epz04620  Toll-like receptor signaling pathway
epz04660  T cell receptor signaling pathway
KO pathway
ko05235   
LinkDB

DBGET integrated database retrieval system